Repare Entered into a Worldwide License and Collaboration Agreement with Roche to Develop and Commercialize Camonsertib (RP-3500) for Cancers
- Repare to receive a $125M up front, ~$1.2B in clinical, regulatory, commercial & sales milestones including ~$55M in near-term fees along with royalties. Roche will be responsible for developing camonsertib & expand its development into additional tumors & multiple combination studies
- If regulatory approval is granted in the US, Repare can opt-in to a 50/50 US co-development & profit share including US co-promotion. If the option is exercised, Repare will continue to receive milestones & Ex-US royalties
- Repare’s SNIPRx platform is designed to develop precision therapies in patients whose tumors have ≥1 genomic alteration & selectively target those tumors in patients with clinical benefit from resulted product candidates
Ref: Businesswire | Image: Roche
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].